Submission Readiness Intelligence
Stress Testing a Regulatory Submission Before FDA Sees It
Executive Summary
A medical device company was preparing a major regulatory submission after several years of development, testing, and evidence generation. Although the team believed the submission package was largely complete, leadership wanted greater confidence that the regulatory strategy, supporting evidence, and core arguments would withstand FDA scrutiny.
Before submission, the company used Agent Astro to conduct a comprehensive readiness assessment.
The platform evaluated the submission package against historical precedents, applicable standards, FDA guidance documents, predicate technologies, and known regulatory expectations. It also stress tested the underlying regulatory rationale, identified potential weaknesses, highlighted unsupported assumptions, and evaluated the impact of alternative FDA interpretations.
The analysis revealed several areas requiring additional clarification and supporting evidence, allowing the organization to strengthen its submission before formal review began.
Key Questions Addressed
Are we truly ready to submit?
Where are the weakest parts of our regulatory argument?
Which claims are most vulnerable to challenge?
What deficiencies might FDA identify?
Have we adequately supported substantial equivalence?
Are our testing and validation activities sufficient?
What risks remain hidden within the submission package?
The Situation
After several years of product development, the company had assembled a comprehensive submission package including:
- •Device descriptions
- •Testing reports
- •Risk management documentation
- •Software validation
- •Biocompatibility assessments
- •Clinical evidence
- •Labeling materials
- •Regulatory justifications
The Challenge
Most submission reviews focus on completeness. Regulators focus on defensibility. A submission may contain thousands of pages of supporting documentation and still contain weaknesses that increase regulatory risk.
Examples include:
- •Unsupported claims
- •Weak predicate comparisons
- •Gaps in evidence
- •Inconsistent terminology
- •Unclear risk justifications
- •Assumptions lacking supporting data
How Agent Astro Approached the Problem
Agent Astro evaluated the submission package as an integrated regulatory argument rather than a collection of individual documents.
Regulatory Argument Analysis
The platform examined:
- Intended use
- Indications
- Claims
- Risk rationale
- Substantial equivalence arguments
To determine whether the overall submission narrative was logically supported.
Evidence Sufficiency Assessment
Agent Astro evaluated:
- Bench testing
- Software validation
- Clinical evidence
- Usability testing
- Cybersecurity documentation
- Standards compliance
Against historical expectations observed in comparable submissions. The goal was to identify areas where evidence may be technically present but strategically insufficient.
Adversarial Regulatory Review
Agent Astro simulated a critical regulatory review process. The system actively searched for:
- Unsupported conclusions
- Missing evidence
- Contradictory information
- Weak justifications
- Regulatory vulnerabilities
This process focused on identifying what could go wrong rather than confirming what appeared correct.
Standards and Guidance Alignment
The platform evaluated consistency between the submission package and:
- Applicable FDA guidance documents
- Recognized standards
- Historical regulatory expectations
To identify areas requiring additional support or clarification.
Predicate and Precedent Validation
The platform reviewed predicate relationships and historical FDA decisions to evaluate whether the proposed regulatory strategy remained well supported.
Alternative interpretations were also explored.
Findings
Several Regulatory Arguments Relied on Assumptions Rather Than Evidence
The submission contained a number of conclusions that appeared reasonable but were not explicitly supported by referenced evidence. These areas became priorities for revision.
Certain Claims Created Unnecessary Regulatory Risk
Several claims introduced additional regulatory complexity without providing significant commercial value. The company identified opportunities to simplify portions of the submission while maintaining its overall objectives.
Predicate Comparisons Could Be Strengthened
Although the proposed predicates remained appropriate, several comparison sections lacked sufficient detail to fully support the intended regulatory argument. Additional analysis improved the robustness of the submission.
Future Reviewer Questions Could Be Anticipated
The analysis identified several topics likely to attract regulatory scrutiny. Addressing these proactively improved confidence in the overall submission strategy.
The Decision
Based on the assessment, the company delayed submission by a short period in order to strengthen key portions of the package.
The team:
- Clarified regulatory arguments
- Strengthened supporting evidence
- Refined predicate comparisons
- Simplified higher-risk claims
- Expanded documentation in selected areas
Outcome
The readiness assessment provided leadership with a clearer understanding of both the strengths and weaknesses of the submission package. Rather than relying solely on internal confidence, the organization evaluated the submission from multiple regulatory perspectives and identified issues while corrective action remained relatively straightforward.
Capabilities Demonstrated
Takeaway
The strongest submissions are not necessarily the largest or most detailed. They are the most defensible. By evaluating evidence, arguments, precedents, and regulatory expectations as a connected system, Agent Astro helps organizations identify weaknesses before regulators do and strengthen submissions before they enter review.
Other Insights & Case Studies
Regulatory Pathway Intelligence
Avoiding a Multi-Million Dollar Regulatory Misstep Before Development Begins
Q-Sub Planning & FDA Engagement Intelligence
Preparing for an FDA Meeting Before Critical Decisions Become Expensive